ライフサイエンスコーパス: STEMI

1 STEMI and SCAD samples were compared by a phosphoproteom

2 STEMI patients presenting <12 h from symptom onset in Ki

3 STEMI-RADIAL (ST Elevation Myocardial Infarction treated

4 STEMIs were classified as inpatient onset or outpatient

5 eeding classifications was assessed in 2,002 STEMI patients undergoing primary percutaneous coronary

6 A total of 62,021 STEMIs were identified in 303 hospitals, of which 3068 (

7 s, 1374 MI events occurred (829 NSTEMIs, 249 STEMIs, 296 unclassifiable MIs).

8 A total of 343 STEMI patients were screened during 15 months enrollment

9 ounts were retrospectively analyzed in 1,377 STEMI patients, and the prognostic relevance of post-PPC

10 40 STEMI patients reperfused by primary percutaneous corona

11 Of 411 STEMI patients (March 11, 2012 to November 21, 2012), 10

12 ry PCI for the presence of QW (early) in 515 STEMI patients.

13 tients with acute myocardial infarction (59% STEMI) admitted to cardiac intensive care units in metro

14 the TIME and Late-TIME trials as well as 61 STEMI patients treated with placebo.

15 We enrolled 738 STEMI patients in this CMR study at 8 centers.

16 In total, 738 STEMI patients reperfused by primary angioplasty were en

17 cytokines in baseline plasma samples from 77 STEMI patients treated with BM-MNCs in the TIME and Late

18 e were 43 hospitals with 1976 AIS and 59 823 STEMI patients.

19 We studied 33,901 STEMI patients transferred for primary percutaneous coro

20 Patients who had a STEMI while hospitalized for a non-ACS condition, compar

21 t CMR predictor of hard clinical events in a STEMI population treated by primary percutaneous coronar

22 pt study, we defined two groups (1) an acute STEMI group (n = 6, 83% male, age 54 +/- 12 years) compl

23 METHODS AND Patients who sustained an acute STEMI were enrolled in a cohort study.

24 to the contemporary PCI management of acute STEMI.

25 r 2013, 23 809 patients presented with acute STEMI (direct to percutaneous coronary intervention hosp

26 tration of ticagrelor in patients with acute STEMI appeared to be safe but did not improve pre-PCI co

27 il 2015, we enrolled 304 patients with acute STEMI who underwent primary PCI and had concurrent CTO i

28 nd the interpretation of evidence addressing STEMI care.

29 rst overall survival (log-rank P=0.04) after STEMI during a median follow-up of 5.2 (3.6, 6.9) years

30 ze measurement was 4 days (3, 10 days) after STEMI.

31 eling and more impaired LV deformation after STEMI compared with those with normal BMI, amid similar

32 entricular (LV) structure and function after STEMI, including LV longitudinal strain (global longitud

33 more than 10% from 1 week to 6 months after STEMI.

34 202 patients (101 per group) 6 months after STEMI.

35 We conclude that plasma profiling after STEMI may help identify patients with a greater likeliho

36 e and MVO with cardiac MR imaging soon after STEMI enables one to make a decision in the prediction o

37 e diagnosis and therapy of LV thrombus after STEMI.

38 telet inhibition during the first year after STEMI.

39 ed coronary artery disease discharged alive, STEMI patients (compared with non-ST-segment-elevation M

40 atients who survive the first month after an STEMI treated with primary PCI have an excellent prognos

41 eated within target time windows for AIS and STEMI (median DTN time <60 minutes: 21% [interquartile r

42 of time-critical care processes for AIS and STEMI in a coordinated approach.

43 Finally, lower PCI hospital annual STEMI volume was a potent predictor of delay.

44 70 patients with Killip class </=II anterior STEMI presenting early after symptom onset (<6 h) and ra

45 In anterior STEMI patients undergoing primary angioplasty, the soone

46 n the overall cohort and in 7.1% in anterior STEMI patients.

47 InfarCtion) trial, which randomized anterior STEMI patients to IV metoprolol or control before mechan

48 In patients with anterior STEMI who had been referred for primary PCI, intravenous

49 ctive, randomized, open-label study assessed STEMI patients undergoing PPCI (n = 52) who were treated

50 Of the 3795 consecutive STEMI patients treated by the use of the Minneapolis Hea

51 enter single-arm study enrolling consecutive STEMI patients undergoing primary percutaneous coronary

52 The current STEMI guidelines might require an update in light of the

53 bsence of left bundle-branch block, definite STEMI (according to both cardiologists) or an ambiguous

54 times and outcomes for patients who develop STEMI after hospital admission.

55 model may serve as an example for developing STEMI systems of care in other low- to middle-income cou

56 cutaneous coronary intervention (PCI) during STEMI using a hub-and-spoke model.

57 Forty-eight STEMI patients were prospectively recruited and underwen

58 ning the unclassifiable MI group with either STEMI or NSTEMI did not change this conclusion.

59 spital performance is correlated on emergent STEMI and AIS care is unknown.

60 l, blinded endpoint clinical trial evaluated STEMI patients with multivessel disease having PPCI with

61 years; age range, 24-89 years) with a first STEMI were prospectively studied.

62 Patients presenting with their first STEMI and early QW in the ECG had smaller myocardial sal

63 ber 2015, patients arriving with their first STEMI were randomized to either DUS intermittent HMI imp

64 After adjustment for STEMI, the benefit of radial access persisted at high-vo

65 ted national rates of hospital admission for STEMI per 100,000 people increased (from 3.5 in 2001, to

66 ast decade in China, hospital admissions for STEMI have risen; in these patients, comorbidities and t

67 y 2 after successful primary angioplasty for STEMI, 53 patients were prospectively enrolled; 40 patie

68 site outcome through 90 days were higher for STEMI patients, whereas risks of mortality and the compo

69 f patients in China admitted to hospital for STEMI in 3 years (2001, 2006, and 2011).

70 All hospitalizations for STEMI in the United States from January 1, 2003, to Dece

71 imary percutaneous coronary intervention for STEMI (77% vs 81%), revascularization for non-STEMI (58%

72 se of percutaneous coronary intervention for STEMI and in-hospital mortality have increased, whereas

73 se of percutaneous coronary intervention for STEMI increased in both younger men (63.9% to 84.8%; ptr

74 (21.9% versus 27.9%; P<0.001) was lower for STEMI patients.

75 Routine thrombus aspiration during PCI for STEMI did not reduce longer-term clinical outcomes and m

76 moral access for patients undergoing PCI for STEMI or other indications (non-ST-segment-elevation myo

77 CTO PCI within 1 week after primary PCI for STEMI was feasible and safe.

78 ical outcomes in patients undergoing PCI for STEMI.

79 within the first year after primary PCI for STEMI.

80 percutaneous coronary intervention (PCI) for STEMI at the University Medical Center Groningen, The Ne

81 safe for older patients undergoing PPCI for STEMI.

82 A total of 707 patients referred for STEMI <12 h of symptom onset were randomized in 4 high-v

83 t group received in-hospital reperfusion for STEMI.

84 less likely to receive revascularization for STEMI and have higher in-hospital mortality as compared

85 We performed medical chart review for STEMI patients transferred for PPCI during a 6-month per

86 dy period although the growth was slower for STEMI than for other indications, P<0.001.

87 tients who underwent successful stenting for STEMI and had left ventricular dysfunction (ejection fra

88 tients who underwent successful stenting for STEMI and had left ventricular dysfunction (ejection fra

89 the largest study of cell-based therapy for STEMI completed in the United States and provides eviden

90 erformance on door-to-balloon (D2B) time for STEMI and door-to-needle (DTN) time for AIS, with and wi

91 for AIS did not correlate with D2B times for STEMI (rho=-0.09; P=0.55).

92 paring CRP-activated systemic platelets from STEMI and SCAD patients, 4 of which were selected for va

93 levels in response to CRP in platelets from STEMI patients, being these levels more pronounced at th

94 e myocardial infarction, 632,930 (46.4%) had STEMI.

95 comorbidities, and lower annual PCI hospital STEMI volumes.

96 ents with onset of symptoms within 12 hours, STEMI, and thrombolysis in myocardial infarction (TIMI)

97 hub-and-spoke model in South India improved STEMI care through greater use of PCI and may improve 1-

98 In STEMI patients undergoing PPCI, crushed prasugrel leads

99 showed a higher response to GPVI agonists in STEMI patients compared to SCAD controls.

100 cardiac magnetic resonance (CMR) findings in STEMI patients with and without diabetes randomized to i

101 BVS implantation in STEMI is feasible and safe and offers excellent 1-year c

102 iographic outcomes after BVS implantation in STEMI.

103 e QW and myocardial salvage index and MVO in STEMI patients treated with primary PCI.

104 he first to describe a stress-induced MVO in STEMI patients.

105 eflow is associated with adverse outcomes in STEMI.

106 The use of radial access for PCI in STEMI is increasing but at a slower pace than for patien

107 , to clarify the benefit from primary PCI in STEMI patients with QW, we examined the association betw

108 The use of TRA for PCI in STEMI was associated with a lower rate of bleeding (11.7

109 percutaneous coronary intervention (PCI) in STEMI and subsequent all-cause mortality, reinfarction,

110 ltered activation state of GPVI signaling in STEMI patients, confirming this receptor as a promising

111 upon hospital admission and infarct size in STEMI patients is a consequence of a larger myocardial a

112 port the use of routine deferred stenting in STEMI patients treated with primary PCI.

113 nger be recommended as a routine strategy in STEMI.

114 itory effects compared with whole tablets in STEMI patients undergoing PPCI.

115 changes in LV function in the longer term in STEMI patients complicated by LV dysfunction.

116 pproved indication of reperfusion therapy in STEMI (streptokinase, tenecteplase, alteplase, and retep

117 rinolytic regimens as reperfusion therapy in STEMI and alteplase (accelerated infusion), tenecteplase

118 ed risk of bleeding and actual use of TRA in STEMI.

119 ST segment elevation myocardial infarction (STEMI) and 42 control subjects.

120 ST segment elevation myocardial infarction (STEMI) and had an emergency PCI performed 2 h upon admis

121 ST-segment-elevation myocardial infarction (STEMI) and non-ST-segment-elevation myocardial infarctio

122 ST-segment elevation myocardial infarction (STEMI) and to investigate the prognostic value of the in

123 ST-segment-elevation myocardial infarction (STEMI) and undergoing primary percutaneous coronary inte

124 ST-segment elevation myocardial infarction (STEMI) and undergoing primary percutaneous coronary inte

125 ST-segment elevation myocardial infarction (STEMI) are less likely to receive revascularization and

126 ST-segment-elevation myocardial infarction (STEMI) are scarce.

127 ST-segment elevation myocardial infarction (STEMI) care are formidable in low- to middle-income coun

128 ST-segment-elevation myocardial infarction (STEMI) guideline goals recommending a first medical cont

129 ST-segment-elevation myocardial infarction (STEMI) has been demonstrated.

130 ST-segment-elevation myocardial infarction (STEMI) has been widely used; however, recent trials have

131 ST-segment-elevation myocardial infarction (STEMI) has decreased drastically.

132 in ST-elevation acute myocardial infarction (STEMI) has no biological inclusion criteria.

133 ST-segment elevation myocardial infarction (STEMI) has not been proved to reduce short-term mortalit

134 ST-segment elevation myocardial infarction (STEMI) in China, no nationally representative studies ha

135 ST-segment elevation myocardial infarction (STEMI) in settings where health-care resources are scarc

136 ST-segment-elevation myocardial infarction (STEMI) is uncertain.

137 vance in ST elevation myocardial infarction (STEMI) is unknown.

138 ST-segment elevation myocardial infarction (STEMI) may not be uniform over time, which may affect th

139 ST-segment elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) who were undergoing PCI and

140 ets from ST-elevation myocardial infarction (STEMI) patients and matched stable coronary artery disea

141 study of ST-elevation myocardial infarction (STEMI) patients who underwent pPCI between Jan 1, 2005,

142 ST-segment-elevation myocardial infarction (STEMI) patients within the time limit of first contact t

143 ST-segment elevation myocardial infarction (STEMI) population.

144 ST-segment elevation myocardial infarction (STEMI) reduces infarct size and improves survival.

145 ST-segment elevation myocardial infarction (STEMI) remains a significant global public health concer

146 ST-segment elevation myocardial infarction (STEMI) remains unknown.

147 ST-segment-elevation myocardial infarction (STEMI) requiring interhospital transfer for primary perc

148 ST-segment-elevation myocardial infarction (STEMI) setting are missing.

149 ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary interven

150 ST-segment elevation myocardial infarction (STEMI) treated with bivalirudin had lower bleeding and m

151 ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary interv

152 ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary interven

153 ST-segment-elevation myocardial infarction (STEMI) victims remain at risk for infarct expansion, hea

154 ST-segment elevation myocardial infarction (STEMI) were randomized 2:1 to BCM or saline injected int

155 ST-segment elevation myocardial infarction (STEMI) who were undergoing percutaneous coronary interve

156 ST-segment elevation myocardial infarction (STEMI), a large multicenter investigation to evaluate th

157 ST-segment elevation myocardial infarction (STEMI), concurrent coronary chronic total occlusion (CTO

158 ST-segment elevation myocardial infarction (STEMI), late gadolinium enhancement (LGE) has been demon

159 ST-segment elevation myocardial infarction (STEMI), the use of percutaneous coronary intervention (P

160 ST segment elevation myocardial infarction (STEMI), with positive cardiac biomarkers and either isch

161 ST-segment-elevation myocardial infarction (STEMI).

162 ST-segment elevation myocardial infarction (STEMI).

163 ST-segment-elevation myocardial infarction (STEMI).

164 ST-segment elevation myocardial infarction (STEMI).

165 ation in ST elevation myocardial infarction (STEMI).

166 ST-segment elevation myocardial infarction (STEMI).

167 ST-segment elevation myocardial infarction (STEMI).

168 ST-segment elevation myocardial infarction (STEMI).

169 ST-segment-elevation myocardial infarction (STEMI).

170 ST-segment elevation myocardial infarction (STEMI).

171 ST-segment elevation myocardial infarction (STEMI).

172 ST-segment elevation myocardial infarction (STEMI).

173 ST-segment elevation myocardial infarction (STEMI).

174 ST-segment elevation myocardial infarction (STEMI).

175 ST-segment elevation myocardial infarction (STEMI).

176 ST-segment-elevation myocardial infarction (STEMI).

177 ST-segment-elevation myocardial infarction (STEMI).

178 ST-segment elevation myocardial infarction (STEMI).

179 ST-segment elevation myocardial infarction [STEMI] and 241 non-ST-segment elevation myocardial infar

180 perintensity was associated with the initial STEMI severity, adverse remodeling, and long-term health

181 alysis allowed for the location of inpatient STEMI to have a multiplicative rather than an additive e

182 This Mission: Lifeline STEMI Systems Accelerator demonstration project represen

183 The Mission: Lifeline STEMI Systems Accelerator program, implemented in 16 US

184 ing for PPCI, arrival at a center with a low STEMI volume, and an ambiguous ECG were independently as

185 ents for those with ST-segment-elevation MI (STEMI) compared with those with non-ST-segment-elevation

186 tes and outcomes of ST-segment elevation MI (STEMI) in renal transplant recipients vs the stage 5D CK

187 ith the type of MI (ST-segment-elevation MI [STEMI] versus non-ST-segment-elevation MI [NSTEMI]) migh

188 In a large, multicenter STEMI population reperfused by primary PCI, CMR markers

189 TEMI (77% vs 81%), revascularization for non-STEMI (58% vs 65%), and prescription of secondary preven

190 t presentation with non-ST elevation MI (non-STEMI) (75% vs 69%).

191 evation myocardial infarction (STEMI) or non-STEMI (NSTEMI) who were undergoing PCI and receiving tre

192 In a nonrestricted STEMI population, early intravenous metoprolol before PP

193 95% confidence interval, 1.39-2.31) but not STEMI (hazard ratio, 0.49; 95% confidence interval, 0.18

194 variation in transfer patterns; only 21% of STEMI receiving hospitals routinely transferred >90% of

195 ving hospitals routinely transferred >90% of STEMI patients to the cath lab directly.

196 agnetic resonance in a multicenter cohort of STEMI patients and (2) prognostic relevance of LV thromb

197 hospitalized with the principal diagnosis of STEMI.

198 heir latest guidelines for the management of STEMI.

199 condition, compared with those with onset of STEMI as an outpatient, were less likely to undergo inva

200 uate associations among location of onset of STEMI, resource utilization, and outcomes.

201 At the early phase of STEMI, the risk of prehospital SCA can be determined thr

202 ond stage we obtained case data for rates of STEMI, treatments, and baseline characteristics from pat

203 Multivessel PCI in the setting of STEMI leads to a small increase in CMR-detected non-IRA

204 nt T2 hyperintensity occurs in two thirds of STEMI patients.

205 Direct transfer of STEMI patients to the cath lab for primary percutaneous

206 d study involving 1862 patients with ongoing STEMI of less than 6 hours' duration, comparing prehospi

207 ient charges were higher for inpatient-onset STEMI (mean length of stay, 13.4 days [95% CI, 12.8-14.0

208 Patients with inpatient-onset STEMI had higher in-hospital mortality (33.6% vs 9.2%; a

209 Patients with inpatient-onset STEMI were older (mean, 71.5 [SD, 13.5] years vs 64.9 [S

210 ; P < .001) than those with outpatient-onset STEMI.

211 In the overall STEMI population (n=8112; median age, 60 years; 78% male

212 ients with left ventricular dysfunction post STEMI who are at risk for death and major morbidity.

213 ients with left ventricular dysfunction post STEMI.

214 rmed in the patients (2 days & 6 months post-STEMI) and the volunteers, and biomechanical heart model

215 apping performed at 2 days and 6 months post-STEMI.

216 ociation jointly published their most recent STEMI guideline statements.

217 Compared with controls, patients with recent STEMI exhibited increased LV wall active tension when no

218 Blood from 59 prospectively recruited STEMI patients undergoing PPCI was sampled, and leukocyt

219 Recurrent STEMI occurred in 2 patients in the deferred stenting gr

220 of the Minneapolis Heart Institute regional STEMI program from March 2003 to January 2013, 990 (26.1

221 largest national effort to organize regional STEMI care.

222 rolled, proof-of-concept trial in reperfused STEMI patients with >/=1 risk factors for no-reflow.

223 In high-risk STEMI patients, deferred stenting in primary PCI reduced

224 catheterization laboratory (cath lab) at the STEMI receiving hospital may expedite reperfusion, but c

225 onary intervention, direct transfer from the STEMI referral hospital to the catheterization laborator

226 The 30-day death rate in the STEMI cohort was 31.2% and 8.5% in the NSTEMI cohort of

227 Two hundred eighty-three STEMI patients (mean age, 59+/-12 years; 75% male) had c

228 rrest, and prolonged door-in door-out time), STEMI referral hospitals' rural location and longer esti

229 d as risk-adjusted rate, >/= 75% of transfer STEMI patients with </= 120-minute first door-to-device

230 More than one third of US STEMI patients transferred for primary PCI fail to achie

231 rred first to the emergency department/ward, STEMI patients transferred to the cath lab had significa

232 infarction admissions, of which 13,815 were STEMI admissions.

233 A total of 6006 patients (3005 with STEMI and 3001 with NSTEMI) were enrolled in the trial.

234 terisation laboratory visits associated with STEMI.

235 older with symptoms or signs consistent with STEMI at primary care clinics, small hospitals, and PCI

236 tality among the renal transplant group with STEMI was markedly lower compared with the stage 5D CKD

237 ) were identified who were hospitalized with STEMI.

238 atients age 18 to 59 years hospitalized with STEMI.

239 A total of 2420 patients with STEMI (2034 men [84.0%] and 386 women [16.0%]; mean [SD]

240 of death in 2,804 consecutive patients with STEMI (age 63 +/- 13 years, 72% males) treated with prim

241 y with PCI versus PCI ALone in Patients with STEMI (TOTAL) was a prospective, randomised, investigato

242 ction) trial evaluated whether patients with STEMI and concurrent CTO in a non-infarct-related artery

243 In patients with STEMI and concurrent CTO, we did not find an overall ben

244 We randomly assigned 885 patients with STEMI and multivessel disease who had undergone primary

245 In patients with STEMI and multivessel disease who underwent primary PCI

246 has decreased considerably for patients with STEMI and NSTEMI.

247 esults were consistent between patients with STEMI and those with NSTEMI and across other major subgr

248 alization for heart failure in patients with STEMI and TIMI grade 0-1 flow at arrival.

249 Identification of the patients with STEMI at higher risk for prehospital SCA could facilitat

250 dispatching and management of patients with STEMI by emergency medical services.

251 Among patients with STEMI cases, 8.3% of the PCI cases were performed via TR

252 ombus aspiration before PCI in patients with STEMI did not reduce the rate of death from any cause or

253 lity consistently decreased in patients with STEMI from 17.2% in 1995 to 6.9% in 2010 and 5.3% in 201

254 In conclusion, the patients with STEMI had serial changes in cardiac complexity.

255 s, treatment, and outcomes for patients with STEMI in China between 2001 and 2011.

256 rove the care and outcomes for patients with STEMI in China.

257 sion date plus 1) among 33,920 patients with STEMI in the linked CathPCI Registry-Centers for Medicar

258 n LD of ticagrelor, 180 mg, in patients with STEMI is feasible and facilitates better early platelet

259 ion-based study evaluating all patients with STEMI managed by emergency medical services in the great

260 Of 79 295 patients with STEMI studied, 2658 (3.4%) patients had prior CABG, of w

261 We randomly assigned 7244 patients with STEMI to undergo manual thrombus aspiration followed by

262 We report outcomes in patients with STEMI undergoing PPCI with or without previous CABG surg

263 In patients with STEMI undergoing primary PCI by operators experienced in

264 n reduces cardiac mortality in patients with STEMI undergoing primary PCI, an effect that can only pa

265 s individual-level relation in patients with STEMI undergoing primary PCI.

266 METHODS AND First patients with STEMI undergoing primary percutaneous coronary intervent

267 me Angiography]) included 2198 patients with STEMI undergoing transport for primary percutaneous coro

268 82 patients with STEMI underwent IACP at PPCI.

269 igures continued to decline in patients with STEMI until 2015, whereas mortality in patients with NST

270 Fifty patients with STEMI were randomized to either chewing an LD of ticagre

271 AMI-3 substudy, a total of 510 patients with STEMI were randomized to PCI with deferred versus immedi

272 y 2007 to January 2013, 34,147 patients with STEMI were treated by PCI with n-DES (n = 4,811), o-DES

273 In patients with STEMI who were being transported for primary percutaneou

274 Among 3,602 patients with STEMI who were enrolled in the HORIZONS-AMI (Harmonizing

275 er mortality gain was found in patients with STEMI with reperfusion therapy or in patients with NSTEM

276 still decreased after 2010 in patients with STEMI without reperfusion therapy, whereas no further mo

277 In a cohort of 772 patients with STEMI, 392 (mean age, 58 years; range, 24-89 years) were

278 Participants included 3602 patients with STEMI, aged 18 years or older, who were undergoing prima

279 In PPCI-treated patients with STEMI, coronary microcirculation begins to recover withi

280 In diabetic patients with STEMI, the administration of intracoronary abciximab imp

281 In this multicenter cohort of patients with STEMI, thrombus prevalence assessed by cardiac magnetic

282 a reperfusion therapy in adult patients with STEMI, whether given alone or in combination with adjunc

283 nostic measure when caring for patients with STEMI.

284 rvention (PCI) alone in 10,732 patients with STEMI.

285 n-hospital outcomes of younger patients with STEMI.

286 om 12% (1995) to 76% (2015) in patients with STEMI.

287 y be safe among selected older patients with STEMI.

288 our after LD administration in patients with STEMI.

289 omparing fibrinolytic drugs in patients with STEMI.

290 ovascular obstruction (MVO) in patients with STEMI.

291 om 66+/-14 to 63+/-14 years in patients with STEMI; it remained stable (68+/-14 years) in patients wi

292 y With PCI Versus PCI Alone in Patients With STEMI]) enrolled 19 047 patients, of whom 18 306 underwe

293 pproach those of the general population with STEMI.

294 on were less likely than men to present with STEMI (adjusted odds ratio [OR]: 0.74; 95% confidence in

295 Medicare data, 17 287 (37.4%) presented with STEMI.

296 history of CABG in patients presenting with STEMI and undergoing PPCI does not independently confer

297 ng patients without diabetes presenting with STEMI and undergoing primary PCI, the use of metformin c

298 ty rates in renal transplant recipients with STEMI are more favorable compared with those of patients

299 Among renal transplant recipients with STEMI, the use of reperfusion increased from 53.7% in th

300 Younger women with STEMI were less likely to receive reperfusion as compare